WO2008098122A3 - Method for treating allergic rhinitis without adverse effects - Google Patents

Method for treating allergic rhinitis without adverse effects Download PDF

Info

Publication number
WO2008098122A3
WO2008098122A3 PCT/US2008/053311 US2008053311W WO2008098122A3 WO 2008098122 A3 WO2008098122 A3 WO 2008098122A3 US 2008053311 W US2008053311 W US 2008053311W WO 2008098122 A3 WO2008098122 A3 WO 2008098122A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
allergic rhinitis
treating allergic
epinastine
present
Prior art date
Application number
PCT/US2008/053311
Other languages
French (fr)
Other versions
WO2008098122A2 (en
Inventor
Ramesh Krishnamoorthy
Original Assignee
Inspire Pharmaceuticals Inc
Ramesh Krishnamoorthy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/770,383 external-priority patent/US20080194544A1/en
Priority claimed from US11/935,245 external-priority patent/US7378082B1/en
Application filed by Inspire Pharmaceuticals Inc, Ramesh Krishnamoorthy filed Critical Inspire Pharmaceuticals Inc
Publication of WO2008098122A2 publication Critical patent/WO2008098122A2/en
Publication of WO2008098122A3 publication Critical patent/WO2008098122A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention is directed to a method for treating allergic rhinitis without causing an adverse effect of bitter taste. The method comprises administering to a patient an aqueous pharmaceutical formulation comprising 0.1- 0.15% (w/v) of epinastine or an acid addition salt thereof, 0.05 -0.5% (w/v) of hydroxypropylmethylcellulose to maintain the viscosity between 1.5-10 centipoise, 1-2% (w/v) of propylene glycol, and a buffer to maintain the pH between 5-8, said aqueous epinastine formulation has a tonicity between 200-400 mOsm/kG; the formulation does not contain a significant amount of a sweetening agent. The present invention provides a method for effectively treating allergic rhinitis by delivering a small volume of the epinastine formulation to the nose of a patient using a small volume metered-dose nasal spray pump. The present method does not cause an adverse effect of bitter taste without including sweetening agents in the formulation.
PCT/US2008/053311 2007-02-08 2008-02-07 Method for treating allergic rhinitis without adverse effects WO2008098122A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US88892607P 2007-02-08 2007-02-08
US60/888,926 2007-02-08
US11/770,383 2007-06-28
US11/770,383 US20080194544A1 (en) 2007-02-08 2007-06-28 Aqueous formulations of epinastine for treating allergic rhinitis
US11/935,245 2007-11-05
US11/935,245 US7378082B1 (en) 2007-11-05 2007-11-05 Method for treating allergic rhinitis without adverse effects

Publications (2)

Publication Number Publication Date
WO2008098122A2 WO2008098122A2 (en) 2008-08-14
WO2008098122A3 true WO2008098122A3 (en) 2008-10-30

Family

ID=39682412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/053311 WO2008098122A2 (en) 2007-02-08 2008-02-07 Method for treating allergic rhinitis without adverse effects

Country Status (1)

Country Link
WO (1) WO2008098122A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6963651B2 (en) * 2020-04-16 2021-11-10 参天製薬株式会社 Aqueous composition containing epinastine or a salt thereof
JP7118579B1 (en) 2020-04-16 2022-08-16 参天製薬株式会社 Aqueous composition containing epinastine or its salt

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471095B1 (en) * 1999-01-13 2002-10-29 The Proctor & Gamble Company Dosing and delivering system
US20040242638A1 (en) * 2001-12-05 2004-12-02 Yanni John M Use of an h1 antagonist and a safe steroid to treat rhinitis
US20050148562A1 (en) * 2000-10-31 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20050288274A1 (en) * 1999-11-12 2005-12-29 Boehringer Ingelheim Pharma Gmbh Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471095B1 (en) * 1999-01-13 2002-10-29 The Proctor & Gamble Company Dosing and delivering system
US20050288274A1 (en) * 1999-11-12 2005-12-29 Boehringer Ingelheim Pharma Gmbh Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane
US20050148562A1 (en) * 2000-10-31 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20040242638A1 (en) * 2001-12-05 2004-12-02 Yanni John M Use of an h1 antagonist and a safe steroid to treat rhinitis

Also Published As

Publication number Publication date
WO2008098122A2 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
US8709508B2 (en) Xylitol-based anti-mucosal compositions and related methods and compositions
US4668513A (en) Method for combating snoring
RU2361593C3 (en) AZELASTINE AND STEROID COMBINATION
PE20070414A1 (en) PHARMACEUTICAL FORMULATIONS INCLUDING 8-HYDROXY-5 - [(1R) -1-HYDROXY-2 - [[(1R) -2- (4-METOXYPHENYL) -1-METHYLETHYL] AMINO] ETHYL] -2 (1H) -QUINOLINONE (CARMOTEROL)
RU2019142130A (en) Compositions containing triptan compounds
WO2006102345A3 (en) Methods and systems for operating an aerosol generator
JP2004525903A5 (en)
MXPA05008909A (en) Intranasal formulation of rotigotine.
NZ510887A (en) Formulations of fexofenadine for ocular and nasal delivery
HUP0203773A2 (en) Solutions containing epinastine
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
JP2022119843A5 (en)
BRPI0406674A (en) Composition for the intranasal administration of fentanyl or a pharmaceutically acceptable salt thereof, use of a pharmaceutically acceptable additive, method for the treatment or prevention of acute or chronic pain, spray device, and process for preparing a composition
WO2003079993A3 (en) hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
WO2008098122A3 (en) Method for treating allergic rhinitis without adverse effects
DK1673074T3 (en) Liquid preparation containing tobramycin
JP2016502991A5 (en)
ATE326947T1 (en) THIXOTROPIC NOSE SPRAY
JP2005533076A (en) Nasal composition comprising mucopolysaccharide and propylene glycol
JP2003502361A5 (en)
JP2000109425A (en) Agent for preventing burst of pollen, prevention of burst of pollen, and agent for cleaning mucous membrane
WO2017180781A1 (en) Magnesium-containing oxytocin formulations and methods of use
BR0316123A (en) Aqueous pharmaceutical formulation, use of an aqueous pharmaceutical formulation, and method of treating a patient in need of antithrombotic treatment
JP5785353B2 (en) Ophthalmic agent
GB2583051A (en) Intranasal epinephrine formulations and methods for the treatment of disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08729287

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08729287

Country of ref document: EP

Kind code of ref document: A2